An Open-label, Single-group, Multi-center, Phase II Clinical Trial Evaluating the Effect of Maintenance DCVAC/OvCa After Standard-of-care Therapy in Women With First Relapse of Platinum-sensitive Epithelial Ovarian Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2018
Price : $35 *
At a glance
- Drugs DCVAC OvCa (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 05 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2017 New trial record
- 28 Nov 2017 This trial is conducted in collaboration with CEEGOG (Central and Eastern European Gynecological Oncology Group), as reported in a SOTIO media release.